Senti Biosciences Holdings Inc(SNTI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.77 | Insider Own | - | Shs Outstand | 31.1M | Perf Week | -10.29% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | -23.08% | Insider Trans | - | Shs Float | 31.1M | Perf Month | -18.44% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.21 | Inst Own | 11.28% | Short Float | 1.68% | Perf Quarter | -68.92% |
| Income | -0.05B | P/S | 158.84 | EPS this Y | 71.43% | Inst Trans | 0.55% | Short Ratio | 2.06 | Perf Half Y | -69.25% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 16.14% | ROA | -97.52% | Short Interest | 0.52M | Perf YTD | -70.58% |
| Book/sh | -0.11 | P/C | 1.48 | EPS past 3/5Y | 50.33% 65.37% | ROE | -466.46% | 52W High | -89.38% ($2.88) | Perf Year | -77.83% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | -82.75% -70.12% | ROIC | -530.66% | 52W Low | 5.52% ($0.29) | Perf 3Y | -95.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 80.28% | Gross Margin | -5630.91% | Volatility(W/M) | 9.72% 10.89% | Perf 5Y | -99.69% |
| Dividend TTM | - | EV/Sales | 388.34 | Sales Y/Y TTM | -100% | Oper. Margin | -102761.82% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.83 | EPS Q/Q | 27.53% | Profit Margin | -90116.36% | RSI (14) | 30.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.83 | Sales Q/Q | - | SMA20 | -17.98% ($0.38) | Beta | 2.23 | Target Price | $15 |
| Payout | - | Debt/Eq | - | Earnings | 2026/08/18 | SMA50 | -37.23% ($0.49) | Rel Volume | 0.43 | Prev Close | $0.3 |
| Employees | 39 | LT Debt/Eq | - | EPS/Sales Surpr. | 24.53% - | SMA200 | -67.14% ($0.94) | Avg Volume(3M) | 0.25M | Price | $0.31 |
| IPO | 2021/5/26 | Option/Short | No/Yes | Trades | 297 | Volume | 108,302 | Change | 1.93% |
Company
SNTI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧫 Senti Biosciences () is a clinical-stage biotech that applies synthetic biology-based "logic gate" design to CAR-NK cell therapy. Its lead candidate, SENTI-202, is an off-the-shelf CAR-NK for acute myeloid leukemia (AML) and has received FDA Orphan Drug and RMAT designations.
Over the past 1 year, on the lower side
89% below its 1-year high.
SNTI has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +71.4% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -95.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 11.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $10M.
SNTI $10M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is SNTI?
SNTI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNTI?
The market cap of SNTI is approximately $10M, ranking 5,533 within its sector.
What is the 52-week high and low for SNTI?
SNTI has recorded a 52-week high of $2.88 and a low of $0.29.
